Guillaume Coulliard

National pharmacare, with a particular focus on access to medicines and rare disease and orphan drug policies Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals including any health technology assessment-related or other policy discussions that might involve Health Canada and its ongoing relationship with Canada's Drug Agency and/or other pan-Canadian health organizations. Regulatory amendments and/or guidelines and/or policies related to the Food and Drugs Act and Health Canada's review of medicines (particularly rare disease treatments). Innovation, Science and Economic Development Canada regarding the Innovation and Skills Agenda, the Biomanufacturing and Life Sciences Strategy and other government policies and programs related to incenting research and development activities in Canada. Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board Engagement with officials on issues related to the National Strategy for Rare Disease Drugs, and other policies or programs related to rare diseases. Federally-funded public drug plans, with respect to reimbursement for drug products for federal plan beneficiaries.